Form 6-K BioLineRx Ltd. For: Nov 22
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/14/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
Roth Capital Affirms BioLineRx (BLRX) at 'Buy' Following Q3 Results
November 22, 2016 2:39 PM ESTRoth Capital affirms BioLineRx (Nasdaq: BLRX) with a Buy rating and $7 price target following Q3 results reported on Tuesday.
The analyst commented, We are encouraged by the multiple collaborations initiated between BLRX and biopharma in both clinical and preclinical staged projects, spanning multiple indications.
We believe that BL-8040 remains the lead value driver for BLRX with 1) partial results for the Phase II study of... More
BioLineRx (BLRX) Tops Q3 EPS by 4c
November 22, 2016 8:07 AM ESTBioLineRx (NASDAQ: BLRX) reported Q3 EPS of ($0.03), $0.04 better than the analyst estimate of ($0.07).
The Company held $38.9 million in cash, cash equivalents and short-term bank deposits as of September 30, 2016.
For earnings history and earnings-related data on BioLineRx (BLRX) click here.
... More